PeLeSeLect & AHEDD
Overcome Mutation Mediated Drug Resistance Platform Technology for Kinase Targeted Precision Drug Design (PeLeSeLect)
1. The Importance of PeLeSeLect Technology
- Kinase Targeted Anti-cancer Drugs → Drug resistant mutations have been frequently evoked in the Gate Keeper Residue and Solvent Front Region within 1-2 years after the treatment to the patients
- PeLeSeLect Drug design platform technology to avoid the risk of drug resistant mutations
2. The Components of PeLeSeLect
- Kinase Active Conformation to design type 1 kinase inhibitor
- Designing technology to target regions with low risk of mutations
- Patentable compound library with new core skeletons and key pharmacophores with properties of type 1 kinase inhibitors
1. The Importance of PeLeSeLect Technology
- Kinase Targeted Anti-cancer Drugs → Drug resistant mutations have been frequently evoked in the Gate Keeper Residue and Solvent Front Region within 1-2 years after the treatment to the patients
- PeLeSeLect Drug design platform technology to avoid the risk of drug resistant mutations
2. The Components of PeLeSeLect
- Kinase Active Conformation to design type 1 kinase inhibitor
- Designing technology to target regions with low risk of mutations
- Patentable compound library with new core skeletons and key pharmacophores with properties of type 1 kinase inhibitors
1. The Importance of PeLeSeLect Technology
- Kinase Targeted Anti-cancer Drugs → Drug resistant mutations have been frequently evoked in the Gate Keeper Residue and Solvent Front Region within 1-2 years after the treatment to the patients
- PeLeSeLect Drug design platform technology to avoid the risk of drug resistant mutations
2. The Components of PeLeSeLect
- Kinase Active Conformation to design type 1 kinase inhibitor
- Designing technology to target regions with low risk of mutations
- Patentable compound library with new core skeletons and key pharmacophores with properties of type 1 kinase inhibitors
Rapid & Highly Efficient AI Platform for Lead Discovery and Optimization AI-Applied High Efficiency Drug Discovery (AHEDD)
- AI-based deep learning of the interaction sites between the target protein and compounds characterizes particular protein sequences of key amino acids in the primary and secondary structures.
- AI-based predictions of drug-target interactions and designing optimized drug structures for the target proteins
- Prediction of hit compound structures interacting with target proteins from library database without the information of their 3D structures
- Experimentally validated platform for the discovery of hit compounds with 3 times fast and maximum 15 times efficient results compared with the hit discovery by traditional random screening protocols
